The Decision Point Before Any Spinout Exists: Inside the Tech Transfer Office
Long before a spinout has a name or a chief executive, a small university office decides whether the science is worth spinning out at all, and that call shapes everything that follows.
The office nobody outside academia has heard of
Every research-intensive UK university has a technology transfer office, sometimes branded as an innovation or enterprise arm, sometimes run through a separate commercialisation company owned by the university. Its job is unglamorous but pivotal: it is the filter through which almost all university research must pass before it can become a product, a licence deal, or a spinout company.
Most people who read about a new spinout imagine a scientist deciding one day to start a business. In practice the process usually begins with a form, not a business plan. Researchers who believe they have made something commercially useful are required, under their employment contract, to submit an invention disclosure to this office. That single administrative step is the real starting gun.
What the office is actually judging
Once a disclosure lands, the tech transfer office is not asking whether the science is good. Peer review and publication already answer that question. It is asking a narrower, harder question: is there a defensible, ownable position here that someone would pay for, and is a company the right vehicle to exploit it?
That assessment typically weighs several things together. Is the invention patentable, or otherwise protectable, and has anything been disclosed publicly that might already have destroyed novelty. Is there a plausible market, and is that market better served by licensing the technology to an existing company or by building a new one around it. How far is the technology from something a customer or investor could actually use, often described using technology readiness levels running from basic principles observed through to a system proven in its operational environment. And, less discussed but decisive in practice, is there someone willing to leave the lab and run it, because investors fund people as much as patents.
Licence or spinout: not the same decision
A common misconception is that all valuable university research becomes a spinout. Far more often it is licensed. If an existing company in the sector could take a patent, a piece of software, or a diagnostic method and slot it into a product line it already sells, licensing is usually faster, cheaper, and lower risk for the university than building a new company from scratch. Spinouts tend to happen when the technology does not fit neatly into any existing business, when it requires years of further development that only a dedicated team will push through, or when the founders themselves are unwilling to hand it to a third party.
This is why two research groups working on superficially similar problems can end up on completely different paths: one licensed quietly to an industrial partner with barely a press release, the other spun out with seed funding and a chief executive within eighteen months.
Proving it before anyone will pay for it
Assuming the office decides a spinout is the right route, the technology is usually still far too early for a venture investor to touch. This is where proof-of-concept funding fills the gap. Universities typically hold internal translational funds, often replenished by returns from earlier successful spinouts, specifically to pay for the unglamorous work of showing a prototype works outside a research lab, building a minimum viable version of a product, or generating the extra data an investor will ask for. National schemes, including funding administered through Innovate UK, exist for exactly this purpose, alongside proof-of-concept and translation grants from research councils and charitable funders in relevant fields.
This stage can take anywhere from months to several years, and a meaningful share of disclosed inventions never make it past it. That is not a failure of the system so much as its intended function: it is far cheaper to establish that an idea will not scale while it is still inside a university lab than after it has raised institutional investment.
Where the office’s job ends
Once a company is incorporated, the tech transfer office’s direct role narrows. It will typically have negotiated the terms on which the university licenses its intellectual property into the new company, agreed the university’s shareholding, and set conditions such as milestones the company must hit to keep its licence. From that point the founders, an appointed board and any new investors take over running the business, while the university retains an equity stake and, usually, the right to be kept informed as the technology it seeded moves further from the lab bench.
Understanding this earlier, quieter stage matters because it explains a lot about why some university science reaches the market as a company at all, while other equally good research simply gets licensed away or shelved. The decision was made in an office most people never hear about, months before anyone announced a spinout.
Where to check specifics
Rules on invention disclosure, university equity policy and available proof-of-concept funding vary by institution and change over time, so always check the current position with the relevant body rather than relying on a fixed figure.